Page last updated: 2024-12-05

omega-aminoenantic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID13580
CHEMBL ID1229507
CHEBI ID181436
SCHEMBL ID35917
MeSH IDM0070771

Synonyms (47)

Synonym
AC-6968
CHEBI:181436
zeta-aminoheptanoic acid
CHEMBL1229507
7-aminoheptanoic acid
heptanoic acid, 7-amino-
929-17-9
nsc-59008
nsc59008
nsc 59008
brn 0906887
amino-enanthylic acid
omega-aminoheptanoic acid
omega-aminoenantic acid
aminoenanthic acid
kyselina 7-aminoenanthova [czech]
einecs 213-197-5
7-aminoenanthic acid
7-aminoheptanoic acid, 98%
7-amino-heptanoic acid
A0311
AKOS000119948
7-aminoheptanoicacid
4-04-00-02791 (beilstein handbook reference)
b10hjx2t48 ,
unii-b10hjx2t48
kyselina 7-aminoenanthova
7-aminooenanthic acid
FT-0633115
AM20120334
7-aminohepentanoic acid
.omega.-aminoheptanoic acid
.omega.-aminoenanthic acid
.zeta.-aminoenanthic acid
aminoenantic acid, omega-
XDOLZJYETYVRKV-UHFFFAOYSA-N
SCHEMBL35917
mfcd00008242
DTXSID10239182
CS-W002042
GS-4263
7-aminoheptanoic acid, purum, >=97.0% (chn)
BP-23845
h-ahp(7)-oh
EN300-17159
Q27274237
Z56896351
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
medium-chain fatty acidAny fatty acid with a chain length of between C6 and C12.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID595477Inhibition of mouse GAT1-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595479Inhibition of mouse GAT3-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595480Inhibition of mouse GAT4-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
AID595478Inhibition of mouse GAT2-mediated [3H]GABA uptake expressed in human HEK cells assessed as specific binding remaining at 1 mM2011European journal of medicinal chemistry, May, Volume: 46, Issue:5
Development of imidazole alkanoic acids as mGAT3 selective GABA uptake inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (8)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (12.50)18.7374
1990's3 (37.50)18.2507
2000's0 (0.00)29.6817
2010's4 (50.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.47

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.47 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.66 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.47)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other8 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]